CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Sanofi (SAN) and GlaxoSmithKline (GSK) announce positive booster data

By Angela Barnes

11:42, 15 December 2021

GlaxoSmithKline logo with a Covid vaccine syringe
GSK and its partner Sanofi announced positive booster data for their coronavirus vaccine candidate. Photo: Shutterstock.

French drugmaker Sanofi and its British partner GlaxoSmithKline (GSK) announced on Wednesday that a single booster dose of their recombinant adjuvanted Covid-19 vaccine candidate has delivered “consistently strong immune responses”.

The companies said in a joint statement that preliminary results from a clinical trial investigating the safety and immunogenicity of the booster showed neutralising antibodies increased regardless of the primary vaccine received - and for all age groups tested.

“The booster was well tolerated, with a safety profile similar to currently approved Covid-19 vaccines. This is the most comprehensive booster trial to date to explore boosting across different vaccine technologies used for primary vaccination,” the businesses said.

Results outcome

Moreover, the partners said the trial will continue to accrue the number of events needed for analysis, with results expected in the first quarter of 2022.

COIN

130.62 Price
+5.430% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 0.26

NVDA

468.39 Price
+0.540% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 0.18

AMZN

146.66 Price
+0.560% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 0.13

TSLA

237.32 Price
+1.340% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 0.11

“These preliminary data show we have a strong booster candidate, whatever primary vaccine you have received,” Thomas Triomphe, executive vice president at Sanofi, said. “This is consistent with our efforts to provide relevant responses to evolving public health needs. While pursuing a phase III trial is a challenge in a quickly shifting pandemic environment, we look forward to seeing the results to support submissions of our booster vaccine as quickly as possible.”

Roger Connor, president of GSK Vaccines, added: “As the pandemic threat continues with the current dominant Delta variant and Omicron rapidly gaining ground, booster vaccines will continue to be needed to help protect people over time. The initial booster data are promising, and we await the phase III results to determine the next steps on making protein-based adjuvanted COVID-19 vaccines available.” 

Read more: Toyota (7203) sees best day since March on $70bn EV investment 

Related topics

Rate this article

Capital Com is an execution-only service provider. The material provided on this website is for information purposes only and should not be understood as an investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page then you do so entirely on your own risk.

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading